Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Protective effects of the succinate/SUCNR1 axis on damaged hepatocytes in NAFLD

  • Marsal Beltran, Anna
  • Llauradó Cabot, Gemma
  • Fernández Veledo, Sonia
Objective: Succinate and succinate receptor 1 (SUCNR1) are linked to fibrotic remodeling in models of non-alcoholic fatty liver disease (NAFLD), but whether they have roles beyond the activation of hepatic stellate cells remains unexplored. We investigated the succinate/SUCNR1 axis in the context of NAFLD specifically in hepatocytes. Methods: We studied the phenotype of wild-type and Sucnr1-/- mice fed a choline-deficient high-fat diet to induce non-alcoholic steatohepatitis (NASH), and explored the function of SUCNR1 in murine primary hepatocytes and human HepG2 cells treated with palmitic acid. Lastly, plasma succinate and hepatic SUCNR1 expression were analyzed in four independent cohorts of patients in different NAFLD stages. Results: Sucnr1 was upregulated in murine liver and primary hepatocytes in response to diet-induced NASH. Sucnr1 deficiency provoked both beneficial (reduced fibrosis and endoplasmic reticulum stress) and detrimental (exacerbated steatosis and inflammation and reduced glycogen content) effects in the liver, and disrupted glucose homeostasis. Studies in vitro revealed that hepatocyte injury increased Sucnr1 expression, which when activated improved lipid and glycogen homeostasis in damaged hepatocytes. In humans, SUCNR1 expression was a good determinant of NAFLD progression to advanced stages. In a population at risk of NAFLD, circulating succinate was elevated in patients with a fatty liver index (FLI) ≥60. Indeed, succinate had good predictive value for steatosis diagnosed by FLI, and improved the prediction of moderate/severe steatosis through biopsy when added to an FLI algorithm. Conclusions: We identify hepatocytes as target cells of extracellular succinate during NAFLD progression and uncover a hitherto unknown function for SUCNR1 as a regulator of hepatocyte glucose and lipid metabolism. Our clinical data highlight the potential of succinate and hepatic SUCNR1 expression as markers to diagnose fatty liver and NASH, respectively., This study was supported by grants from MCIN/AEI/10.13039/501100011033 (SAF2015-65019-R, RTI2018-093919-B-100 and PID2021-122480OB-100 to S.F.-V.; PID2021-122766OB-100 to A.M.V; PID2021-124425OB-I00 to P.A.) co-financed by the European Regional Development Fund (ERDF) and Grupos consolidados Gobierno Vasco IT1476-22 to P.A. This research was funded by the Institute of Health “Carlos III” (ISCIII) and co-financed by ERDF (PI20/00095 to V.C.-M.; PI20/00338 to J.V. and PI20/00505 to B.R.-M.). This study was also supported by a grant from ISCIII and CIBERDEM, DEM19PI01/2019 to V.C.-M. and P.R. The project that gave rise to these results received funding from “La Caixa” Foundation (ID 100010434), under the grant agreement LCF/PR/HR20/52400013 (to S.F.-V.). This study was also supported by Rovira i Virgili University and Tarragona Provincial Council with the Talent Salut fellowship to A.R.-C. A.M.-B. is a recipient of an FPU grant (FPU20/05633) from MCIN/AEI/10.13039/501100011033. B.A. acknowledges support from the PERIS program 2016–2020 (LT017/20/000033), from Departament de Salut de la Generalitat de Catalunya. V.C.-M. acknowledges support from the Ramón y Cajal program (RYC2019-02649-I), from MCIN/AEI/10.13039/501100011033/ and the European Social Fund (ESF), “Investing in your future”. B.R.-M. acknowledges support from the Miguel Servet Type I program (CP19/00098) from the Fondo de Investigación Sanitaria, co-financed by the ERDF. SFV and JVO acknowledge support from the Agency for Management of University Research Grants of the Generalitat de Catalunya (2021 SGR 01409, 2021 SGR 0089). The study was also supported by CIBER–Consorcio Centro de Investigación Biomédica en Red (CB07708/0012), ISCIII, Ministerio de Ciencia e Innovación.
Repositori Obert UdL
Publicación Artículo científico (JournalArticle)

Circulating short‑chain fatty acids and Mediterranean food patterns. A potential role for the prediction of type 2 diabetes risk: The Di@bet.es Study

  • Llauradó, Gemma
  • Cedó Giné, Lídia
  • Climent, Elisenda
  • Badia, Joan
  • Rojo‑Martínez, Gemma
  • Flores‑Le Roux, Juana
  • Yanes, Óscar
  • Vinaixa, Maria
  • Granado Casas, Minerva
  • Mauricio Puente, Dídac
Background: Identifying nutritional patterns associated with developing type 2 diabetes (T2D) can facilitate more effective and personalized dietary interventions. Short-chain fatty acids (SCFAs), key metabolites derived from gut microbiota, are produced through the anaerobic fermentation of dietary fibers. This study aimed to evaluate whether circulating concentrations of SCFAs are associated with specific food consumption patterns and to assess their association with T2D development in at-risk subjects within a prospective cohort (The Di@bet.es Study). Methods: The Di@bet.es study is a prospective, population-based study utilizing random cluster sampling from the Spanish population aged over 18 years (n=5,072). Among these participants, 4,347 were free of T2D at baseline. Follow-up losses were approximately 45%, resulting in a final re-screened sample of 2,408 subjects. A qualitative food frequency questionnaire evaluated Mediterranean diet (MedDiet) adherence and high-fiber food consumption. The risk of developing T2D was assessed using the FINDRISK. Metabolomics-driven analyses of SCFAs were conducted using gas chromatography-mass spectrometry. Results: Subjects who developed T2D after a median follow-up of seven years had higher baseline circulating concentrations of butyrate and isobutyrate. Circulating concentrations of SCFAs were associated with high-fiber food consumption at baseline. In multivariate analysis, baseline circulating concentrations of butyrate and isobutyrate were independently associated with incident T2D after adjusting for traditional clinical factors. The C-statistics for predicting T2D were 0.847 (95%CI:0.816–0.877) for butyrate and 0.843 (95%CI:0.812–0.875) for isobutyrate in adjusted models, similar to the reference model based on traditional clinical factors (0.840 [95%CI: 0.807–0.873]). Both models improved risk prediction compared to FINDRISK. Dietary patterns did not add predictive value. Sensitivity analysis excluding subjects with prediabetes at baseline confirmed these results. In addition, an association between baseline consumption of high-fiber foods with incident T2D emerged, suggesting a different behaviour between healthy and prediabetic subjects. Conclusions: Baseline circulating concentrations of SCFAs are associated with high-fiber food consumption and independently predict the development of T2D over seven years of follow-up. However, they offer limited improvement in risk prediction compared to traditional risk factors, though they enhance risk prediction as assessed by FINDRISK. Further studies are necessary to evaluate the impact of dietary interventions on SCFA., The authors acknowledge the financial support provided through the project PI20/00312 (GL), funded by the Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union, as well as through the project “XII Ayudas SED a Proyectos de Investigación Clínica en Diabetes dirigidos por jóvenes investigadores,” funded by the Sociedad Española de Diabetes (GL). Research conducted in the authors’ laboratory is supported by grants from the ISCIII (PI20/00338 and PI23/01133 to JV; PI18/0328 and PI21/01163 to DM) and the Spanish Ministry of Science and Innovation MCIN/AEI/https://doi.org/10.13039/501100011033(RTI2018-093919-B-100 and PID2021-122480OB-584–100 to SFV, and PID2020-119030RJ-I00 to LC), all co-financed by the European Regional Development Fund (ERDF). Additional financial support was provided by the CIBER -Consorcio Centro de Investigación Biomédica en Red (CB07708/0012), ISCIII, Ministerio de Ciencia e Innovación, and by the "La Caixa" Foundation (ID 100010434) under grant agreement LCF/PR/HR20/52400013 (to SFV). SFV and JV also acknowledge support from the Agency for Management of University Research Grants of the Generalitat de Catalunya (2021 SGR 01409, 2021 SGR 0089)., The authors acknowledge the financial support provided through the project PI20/00312 (GL), funded by the Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union, as well as through the project “XII Ayudas SED a Proyectos de Investigación Clínica en Diabetes dirigidos por jóvenes investigadores,” funded by the Sociedad Española de Diabetes (GL). Research conducted in the authors’ laboratory is supported by grants from the ISCIII (PI20/00338 and PI23/01133 to JV; PI18/0328 and PI21/01163 to DM) and the Spanish Ministry of Science and Innovation MCIN/AEI/https://doi.org/10.13039/501100011033(RTI2018-093919-B-100 and PID2021-122480OB-584–100 to SFV, and PID2020-119030RJ-I00 to LC), all co-financed by the European Regional Development Fund (ERDF). Additional financial support was provided by the CIBER -Consorcio Centro de Investigación Biomédica en Red (CB07708/0012), ISCIII, Ministerio de Ciencia e Innovación, and by the "La Caixa" Foundation (ID 100010434) under grant agreement LCF/ PR/HR20/52400013 (to SFV). SFV and JV also acknowledge support from the Agency for Management of University Research Grants of the Generalitat de Catalunya (2021 SGR 01409, 2021 SGR 0089).
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Protective effects of the succinate/SUCNR1 axis on damaged hepatocytes in NAFLD

  • Marsal Beltran, Anna
  • Llauradó Cabot, Gemma
  • Fernández Veledo, Sonia
Objective: Succinate and succinate receptor 1 (SUCNR1) are linked to fibrotic remodeling in models of non-alcoholic fatty liver disease (NAFLD), but whether they have roles beyond the activation of hepatic stellate cells remains unexplored. We investigated the succinate/SUCNR1 axis in the context of NAFLD specifically in hepatocytes. Methods: We studied the phenotype of wild-type and Sucnr1-/- mice fed a choline-deficient high-fat diet to induce non-alcoholic steatohepatitis (NASH), and explored the function of SUCNR1 in murine primary hepatocytes and human HepG2 cells treated with palmitic acid. Lastly, plasma succinate and hepatic SUCNR1 expression were analyzed in four independent cohorts of patients in different NAFLD stages. Results: Sucnr1 was upregulated in murine liver and primary hepatocytes in response to diet-induced NASH. Sucnr1 deficiency provoked both beneficial (reduced fibrosis and endoplasmic reticulum stress) and detrimental (exacerbated steatosis and inflammation and reduced glycogen content) effects in the liver, and disrupted glucose homeostasis. Studies in vitro revealed that hepatocyte injury increased Sucnr1 expression, which when activated improved lipid and glycogen homeostasis in damaged hepatocytes. In humans, SUCNR1 expression was a good determinant of NAFLD progression to advanced stages. In a population at risk of NAFLD, circulating succinate was elevated in patients with a fatty liver index (FLI) ≥60. Indeed, succinate had good predictive value for steatosis diagnosed by FLI, and improved the prediction of moderate/severe steatosis through biopsy when added to an FLI algorithm. Conclusions: We identify hepatocytes as target cells of extracellular succinate during NAFLD progression and uncover a hitherto unknown function for SUCNR1 as a regulator of hepatocyte glucose and lipid metabolism. Our clinical data highlight the potential of succinate and hepatic SUCNR1 expression as markers to diagnose fatty liver and NASH, respectively., This study was supported by grants from MCIN/AEI/10.13039/501100011033 (SAF2015-65019-R, RTI2018-093919-B-100 and PID2021-122480OB-100 to S.F.-V.; PID2021-122766OB-100 to A.M.V; PID2021-124425OB-I00 to P.A.) co-financed by the European Regional Development Fund (ERDF) and Grupos consolidados Gobierno Vasco IT1476-22 to P.A. This research was funded by the Institute of Health “Carlos III” (ISCIII) and co-financed by ERDF (PI20/00095 to V.C.-M.; PI20/00338 to J.V. and PI20/00505 to B.R.-M.). This study was also supported by a grant from ISCIII and CIBERDEM, DEM19PI01/2019 to V.C.-M. and P.R. The project that gave rise to these results received funding from “La Caixa” Foundation (ID 100010434), under the grant agreement LCF/PR/HR20/52400013 (to S.F.-V.). This study was also supported by Rovira i Virgili University and Tarragona Provincial Council with the Talent Salut fellowship to A.R.-C. A.M.-B. is a recipient of an FPU grant (FPU20/05633) from MCIN/AEI/10.13039/501100011033. B.A. acknowledges support from the PERIS program 2016–2020 (LT017/20/000033), from Departament de Salut de la Generalitat de Catalunya. V.C.-M. acknowledges support from the Ramón y Cajal program (RYC2019-02649-I), from MCIN/AEI/10.13039/501100011033/ and the European Social Fund (ESF), “Investing in your future”. B.R.-M. acknowledges support from the Miguel Servet Type I program (CP19/00098) from the Fondo de Investigación Sanitaria, co-financed by the ERDF. SFV and JVO acknowledge support from the Agency for Management of University Research Grants of the Generalitat de Catalunya (2021 SGR 01409, 2021 SGR 0089). The study was also supported by CIBER–Consorcio Centro de Investigación Biomédica en Red (CB07708/0012), ISCIII, Ministerio de Ciencia e Innovación.